{"entity":{"id":"blueprint-medicines","kind":"company","name":"Blueprint Medicines","aka":[],"tldr":"Blueprint Medicines invented Ayvakit, a pill approved for systemic mastocytosis and for a rare gut tumour called GIST that carries a specific mutation. The French drug maker Sanofi bought the company in 2025.","summary":"Blueprint Medicines is a Cambridge, Massachusetts kinase medicine company, now a Sanofi company. Its approved product, Ayvakit/Ayvakyt (avapritinib), is a KIT and PDGFRA inhibitor approved for advanced and indolent systemic mastocytosis and, per the company's site, for certain gastrointestinal stromal tumours (GIST). The pipeline includes elenestinib, a next-generation KIT inhibitor for systemic mastocytosis, and BLU-808, an oral wild-type KIT inhibitor for mast cell-driven allergic and inflammatory disease. Sanofi and Blueprint announced a definitive agreement on 2 June 2025 at 129 US dollars per share in cash (about 9.1 billion US dollars equity value) plus a contingent value right of up to 6 US dollars per share; the tender offer expired on 17 July 2025 with about 70.9 percent of shares tendered and the merger closed shortly after. Blueprint's former Nasdaq ticker was BPMC.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.blueprintmedicines.com/"},{"label":"Sanofi acquisition announcement (SEC exhibit)","url":"https://www.sec.gov/Archives/edgar/data/1597264/000110465925055143/tm2516831d1_ex99-1.htm"},{"label":"Tender offer completion 8-K (SEC)","url":"https://www.sec.gov/Archives/edgar/data/1597264/000119312525160804/d909980d8k.htm"}],"tags":[],"related":[],"cancers":["sarcoma"],"sections":["targeted-therapy"],"technologies":["kinase-inhibitors"],"targets":["kit"],"drugs":["pralsetinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07629960"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year and IPO (2015) not sourced. The company website blocked curl (Cloudflare) but was fetched successfully with WebFetch. The GIST indication statement rests on the website summary; the Sanofi release frames the deal around systemic mastocytosis and immunology."],"hq":"Cambridge, MA","country":"US","companyType":"biotech","website":"https://www.blueprintmedicines.com/","stage":"acquired","investors":[],"funding":[{"round":"Acquisition","year":2025,"amountUsd":9100000000,"source":"https://www.sec.gov/Archives/edgar/data/1597264/000110465925055143/tm2516831d1_ex99-1.htm","note":"129 US dollars per share in cash (equity value about 9.1 billion) plus a contingent value right worth up to 6 US dollars per share for BLU-808 milestones; tender offer completed July 2025"}],"acquiredBy":"sanofi"},"route":"/companies/blueprint-medicines/","neighbours":{"cancer":[{"id":"ret-fusion-nsclc","kind":"cancer","name":"RET fusion-positive non-small-cell lung cancer","route":"/cancers/ret-fusion-nsclc/"},{"id":"sarcoma","kind":"cancer","name":"Sarcomas (soft tissue, bone, GIST)","route":"/cancers/sarcoma/"}],"section":[{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"technology":[{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"target":[{"id":"kit","kind":"target","name":"KIT","route":"/targets/kit/"}],"drug":[{"id":"pralsetinib","kind":"drug","name":"Pralsetinib","route":"/drugs/pralsetinib/"}],"trial":[{"id":"nct07629960","kind":"trial","name":"A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations","route":"/trials/nct07629960/"},{"id":"arrow-thyroid","kind":"trial","name":"ARROW (thyroid cohorts)","route":"/trials/arrow-thyroid/"},{"id":"explorer","kind":"trial","name":"EXPLORER","route":"/trials/explorer/"},{"id":"navigator","kind":"trial","name":"NAVIGATOR","route":"/trials/navigator/"},{"id":"voyager","kind":"trial","name":"VOYAGER","route":"/trials/voyager/"}],"company":[{"id":"boxer-capital","kind":"company","name":"Boxer Capital","route":"/companies/boxer-capital/"},{"id":"sanofi","kind":"company","name":"Sanofi","route":"/companies/sanofi/"}]}}